CNS Demyelination with TNF-α Blockers.
CNS Demyelination with TNF-α Blockers.
复制标题
DOI：
10.1007/s11910-017-0742-1
复制
发表时间：
2017-04
影响因子：
5.6
通讯作者：
Andreadou E
中科院分区：
文献类型：
--
作者：
Kemanetzoglou E;Andreadou E
肿瘤坏死因子-α(肿瘤坏死因子-α)阻滞剂是治疗多种炎症性疾病的常用药物。到目前为止，已有5种肿瘤坏死因子-α阻滞剂被批准临床使用(依那西普、英夫利昔单抗、阿达单抗、戈利单抗)。和Certolizumab)。尽管被认为是相对安全的，但已有报道与免疫抑制相关的严重副作用，包括中枢和外周神经系统(CNS)脱髓鞘障碍。这些事件是仅仅是巧合还是使用抗肿瘤坏死因子-α的副作用仍然难以捉摸。在本文中，我们回顾了已发表的与抗肿瘤坏死因子-α治疗相关的中枢神经系统脱髓鞘的病例报道，并介绍了我们之前报道的4例患者在接受抗肿瘤坏死因子-α治疗后出现神经脱髓鞘症状的随访情况。我们还讨论了肿瘤坏死因子-α阻滞剂在脱髓鞘中的可能作用。
Tumor necrosis factor–α (TNF-α) blockers are a popular therapeutic choice in a number of inflammatory diseases. Thus far, five TNF- α blockers have been approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and certolizumab). Despite being considered relatively safe, serious side effects associated with immune suppression have been reported, including central and peripheral nervous system (CNS) demyelinating disorders. It is still elusive whether these events are mere coincidence or a side effect of anti-TNF-α use. In this paper, we review the published case reports of CNS demyelination associated with anti-TNF-α therapy and present the follow-up of our 4 previously reported patients who developed neurologic symptoms suggestive of CNS demyelination after having received anti-TNF-α treatment. We also discuss the possible role of TNF-α blockers in demyelination.